JP2011511012A5 - - Google Patents

Download PDF

Info

Publication number
JP2011511012A5
JP2011511012A5 JP2010545328A JP2010545328A JP2011511012A5 JP 2011511012 A5 JP2011511012 A5 JP 2011511012A5 JP 2010545328 A JP2010545328 A JP 2010545328A JP 2010545328 A JP2010545328 A JP 2010545328A JP 2011511012 A5 JP2011511012 A5 JP 2011511012A5
Authority
JP
Japan
Prior art keywords
rifabutin
clofazimine
clarithromycin
medicament
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010545328A
Other languages
English (en)
Japanese (ja)
Other versions
JP5572872B2 (ja
JP2011511012A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/000129 external-priority patent/WO2009097651A1/en
Publication of JP2011511012A publication Critical patent/JP2011511012A/ja
Publication of JP2011511012A5 publication Critical patent/JP2011511012A5/ja
Application granted granted Critical
Publication of JP5572872B2 publication Critical patent/JP5572872B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010545328A 2008-02-08 2009-02-05 炎症性腸疾患を治療するための方法および組成物 Active JP5572872B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6514408P 2008-02-08 2008-02-08
US61/065,144 2008-02-08
PCT/AU2009/000129 WO2009097651A1 (en) 2008-02-08 2009-02-05 Methods and compositions for treating inflammatory bowel disease

Publications (3)

Publication Number Publication Date
JP2011511012A JP2011511012A (ja) 2011-04-07
JP2011511012A5 true JP2011511012A5 (https=) 2012-03-22
JP5572872B2 JP5572872B2 (ja) 2014-08-20

Family

ID=40951740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010545328A Active JP5572872B2 (ja) 2008-02-08 2009-02-05 炎症性腸疾患を治療するための方法および組成物

Country Status (18)

Country Link
US (10) US8343511B2 (https=)
EP (2) EP3391882A1 (https=)
JP (1) JP5572872B2 (https=)
AU (1) AU2009212097B2 (https=)
CA (1) CA2714043C (https=)
CY (1) CY1121465T1 (https=)
DK (1) DK2247291T3 (https=)
ES (1) ES2708087T3 (https=)
HR (1) HRP20190045T1 (https=)
HU (1) HUE041305T2 (https=)
IL (1) IL207420A (https=)
NZ (1) NZ587250A (https=)
PL (1) PL2247291T3 (https=)
PT (1) PT2247291T (https=)
SI (1) SI2247291T1 (https=)
TR (1) TR201819940T4 (https=)
WO (1) WO2009097651A1 (https=)
ZA (1) ZA201005735B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2247291T (pt) 2008-02-08 2019-02-01 Red Hill Biopharma Ltd Métodos e composições para tratamento de doença inflamatória do intestino
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
US20150017673A1 (en) 2012-08-30 2015-01-15 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell
WO2015123392A1 (en) * 2014-02-14 2015-08-20 The Texas A&M University System Compositions and methods for inhibition of angiogenesis and lymphangiogenesis
EP3145510B8 (en) * 2014-05-22 2021-10-27 Kuenstner, John, Todd Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
WO2017060771A2 (en) 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
CN107202848B (zh) * 2017-07-24 2022-11-15 浙江华海药业股份有限公司 一种氯法齐明的液相色谱分析方法
US11321665B2 (en) * 2017-08-29 2022-05-03 Weightrx Inc. System and method of automated tracking of consumable products
US11351158B2 (en) * 2019-09-12 2022-06-07 BioVersys AG Rifabutin treatment methods, uses, and compositions
WO2022003421A2 (en) * 2020-06-30 2022-01-06 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
US20240230666A1 (en) * 2021-03-25 2024-07-11 The Regents Of The University Of Michigan Compositions and methods for detecting, preventing, and treating disturbed microbiota-immune homeostasis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
EP0971735B1 (en) * 1997-04-01 2008-03-19 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
PT2247291T (pt) 2008-02-08 2019-02-01 Red Hill Biopharma Ltd Métodos e composições para tratamento de doença inflamatória do intestino

Similar Documents

Publication Publication Date Title
JP2011511012A5 (https=)
US11877995B2 (en) Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases
AU2022340500A1 (en) Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma
Jackson et al. Long-acting rilpivirine for HIV prevention
RU2699545C2 (ru) Применение эрибулина в лечении рака
JP5572872B2 (ja) 炎症性腸疾患を治療するための方法および組成物
EP2758061B1 (en) Combination of antibiotics for treating an autoimmune disease
Perez-Molina et al. Use of methotrexate for leprosy reactions. Experience of a referral center and systematic review of the literature
WO2023049920A1 (en) Combination comprising atogepant for treating migraine
JP6454436B1 (ja) ペマフィブラートを含有する医薬
Fok et al. Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers
US20140275138A1 (en) Method and products for treating diabetes
Anadón et al. Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats
CN104490796B (zh) 注射用地塞米松磷酸钠药物组合物和制法
Isles et al. A randomised double-blind study comparing nifedipine GITS 20 mg and bendrofluazide 2.5 mg administered once daily in mild-to-moderate hypertension
Hu et al. A randomized, placebo-controlled phase Ib/IIa trial to evaluate the safety, tolerability, and efficacy of BGT-002, an adenosine triphosphate citrate lyase inhibitor in patients with NAFLD: interim analysis
Quinson et al. Steady state evaluation of two extended release (XR) nevirapine (NVP) tablets 400 mg QD compared with immediate release (IR) NVP tablets 200 mg BID in HIV-1 infected patients
WO2006093774A2 (en) Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy
CN121846105A (zh) 谷氨酰胺在治疗原发性肾病综合征中的用途及其应用
CN114344328A (zh) 降低高血压患者痛风发生风险的组合物
RIFAMPICIN EFFECT OF MULTIPLE DOSES OF FENOFIBRATE ON THE PHARMACOKINETICS OF PRAVASTATIN. LE Gustavson, PhD, SM Schweitzer, S. Koehne-Voss, R. Achari, PhD, T. Chira, H. Esslinger, MD, HD Yannicelli, MD, Abbott Laboratories, Ab-bott Park, IL.
Ständer et al. I. PHARMACOLOGY OF OPIOID RECEPTOR ANTAGONISTS
Al Saghier et al. SUCCESSFUL LIVING RELATED DONOR KIDNEY TRANSPLANTATION AFTER TREATMENT OF POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) USING HUMANIZED ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB).: 19
Song et al. CLINICAL USEFULNESS OF SERUM C-REACTIVE PROTEIN (CRP) IN ADULT LIVING DONOR LIVER TRANSPLANTATION (LDLT) PATIENT: DIAGNOSTIC ACCURACY FOR INFECTION AND ACUTE CELLULAR REJECTION (ACR).: 20